Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.
Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.
复制标题
作者：
He R;Zheng M;Lian L;Yao X
(1)背景：这项纵向研究的目的是评估中国肌萎缩侧索硬化症(ALS)患者Milano-Torino分期(MITOS)的疾病进展与长期生存的关系。我们还检查了影响Mitos进展的因素。(2)对入选患者分别于6、12、18、24个月进行随访，评价患者的人口统计学和临床资料，包括Milano-Torino分期、肌萎缩侧索硬化症功能评定量表修订版(ALSFRS-R)评分和神经精神病学资料。比较从基线到6个月基于Mitos进展和ALSFRS-R评分下降来预测生存结果的敏感性和特异性。检查从基线到6个月的Mitos进展与12、18和24个月的生存结果之间的关系，并用亚组分析评估与疾病进展相关的因素。(3)结果：在纳入的100例患者中，74%的患者在基线时处于0期，大约95%的患者在24个月时进展到MITOS系统的更高阶段。从基线到6个月的Mitos进展和ALSFRS-R的下降在预测12、18和24个月的生存方面显示出类似的价值。米托斯从基线进展到6个月与死亡结局密切相关。发病年龄较大以及抑郁和焦虑评分增加可能与疾病进展有关。(4)结论：早期病程中的Mitos进展可作为长期生存的预后指标，有可能在临床试验中应用。发病年龄、诊断和神经精神因素可能与疾病进展有关。
(1) Background: The aim of this longitudinal study was to evaluate the association between disease progression according to the Milano–Torino staging (MITOS) system and long-term survival in Chinese patients with amyotrophic lateral sclerosis (ALS). We also examined factors affecting MITOS progression. (2) Methods: Patients were enrolled and underwent follow-up at 6, 12, 18, and 24 months, and their demographic and clinical data, including the Milano–Torino stage, Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised (ALSFRS-R) score and neuropsychiatric data, were evaluated. The sensitivity and specificity of predicting survival outcomes based on MITOS progression and ALSFRS-R score decline from baseline to 6 months were compared. The associations between MITOS progression from baseline to 6 months and survival outcome at 12, 18 and 24 months were examined, and factors associated with disease progression were evaluated with subgroup analyses. (3) Results: Among the 100 patients included, 74% were in stage 0 at baseline, and approximately 95% progressed to a higher stage of the MITOS system at 24 months. MITOS progression from baseline to 6 months and ALSFRS-R decline showed comparable value for predicting survival at 12, 18, and 24 months. MITOS progression from baseline to 6 months is strongly associated with death outcomes. Older age at onset and increased depression and anxiety scores may be related to disease progression. (4) Conclusions: MITOS progression during the early disease course could serve as a prognostic marker of long-term survival and may have utility in clinical trials. Age at onset and diagnosis and neuropsychiatric factors might be associated with disease progression.
登录
查看更多内容
DOI：
10.1093/brain/awr351
发表时间：
2012-03
期刊：
Brain : a journal of neurology
影响因子：
--
作者：
Roche JC;Rojas-Garcia R;Scott KM;Scotton W;Ellis CE;Burman R;Wijesekera L;Turner MR;Leigh PN;Shaw CE;Al-Chalabi A
通讯作者：
Al-Chalabi A
影响因子：
11.2
作者：
Kaufmann, Petra;Thompson, John L. P.;Levy, Gilberto;Buchsbaum, Richard;Shefner, Jeremy;Krivickas, Lisa S.;Katz, Jonathan;Rollins, Yvonne;Barohn, Richard J.;Jackson, Carlayne E.;Tiryaki, Ezgi;Lomen-Hoerth, Catherine;Armon, Carmel;Tandan, Rup;Rudnicki, Stacy A.;Rezania, Kourosh;Sufit, Robert;Pestronk, Alan;Novella, Steven P.;Heiman-Patterson, Terry;Kasarskis, Edward J.;Pioro, Erik P.;Montes, Jacqueline;Arbing, Rachel;Vecchio, Darleen;Barsdorf, Alexandra;Mitsumoto, Hiroshi;Levin, Bruce
通讯作者：
Levin, Bruce
影响因子：
9.9
作者：
Crockford C;Newton J;Lonergan K;Chiwera T;Booth T;Chandran S;Colville S;Heverin M;Mays I;Pal S;Pender N;Pinto-Grau M;Radakovic R;Shaw CE;Stephenson L;Swingler R;Vajda A;Al-Chalabi A;Hardiman O;Abrahams S
通讯作者：
Abrahams S
影响因子：
4.4
作者：
Cedarbaum, JM;Stambler, N;Nakanishi, A
通讯作者：
Nakanishi, A
DOI：
10.1080/21678421.2018.1550516
发表时间：
2019-01-02
影响因子：
2.8
作者：
Chen, Xueping;Wei, Qian-Qian;Shang, Huifang
通讯作者：
Shang, Huifang